Meeting
2018 ASCO Annual Meeting
Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).
Authors
Noura Choudhury
The University of Chicago, Chicago, IL
Noura Choudhury , Patrick Evans , James N. Ingle , Ingrid A. Mayer , Phuong Khanh H. Morrow , Anna Maria Storniolo , Andres Forero-Torres , Catherine H. Van Poznak , Douglas E. Merkel , Elizabeth Claire Dees , Gini F. Fleming , Olwen Mary Hahn , Philip C. Hoffman , Olufunmilayo I. Olopade , Nancy Cox , Rita Nanda , Peter H. O'Donnell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT00977119
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1071)
DOI
10.1200/JCO.2018.36.15_suppl.1071
Abstract #
1071
Poster Bd #
152
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).
First Author: Yan Yang
Poster
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
First Author: Biyun Wang
Poster
2023 ASCO Annual Meeting
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
First Author: Rinath Jeselsohn
Poster
2022 ASCO Annual Meeting
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
First Author: Qiang Zhang